Arsenic Trioxide Is a Potent Inhibitor of the Interaction of SMRT Corepressor with Its Transcription Factor Partners, Including the PML-Retinoic Acid Receptor α Oncoprotein Found in Human Acute Promyelocytic Leukemia

ABSTRACT The SMRT corepressor complex participates in transcriptional repression by a diverse array of vertebrate transcription factors. The ability to recruit SMRT appears to play a crucial role in leukemogenesis by the PML-retinoic acid receptor α (RARα) oncoprotein, an aberrant nuclear hormone receptor implicated in human acute promyelocytic leukemia (APL). Arsenite induces clinical remission of APL through a incompletely understood mechanism. We report here that arsenite is a potent inhibitor of the interaction of SMRT with its transcription factor partners, including PML-RARα. Arsenite operates, in part, through a mitogen-activated protein (MAP) kinase cascade culminating in phosphorylation of the SMRT protein, dissociation of SMRT from its nuclear receptor partners, and a relocalization of SMRT out of the nucleus into the cytoplasm of the cell. Conversely, inhibition of this MAP kinase cascade attenuates the effects of arsenite on APL cells. Our results implicate SMRT as an important biological target for the actions of arsenite in both normal and neoplastic cells.

[1]  R. Evans,et al.  Identification of a nuclear domain with deacetylase activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Privalsky,et al.  The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export , 2000, Molecular and Cellular Biology.

[3]  J. Qin,et al.  Both corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3 , 2000, The EMBO journal.

[4]  S. Minucci,et al.  Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. , 2000, Molecular cell.

[5]  R. Evans,et al.  Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. , 2000, Molecular cell.

[6]  R. Evans,et al.  Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. , 2000, Genes & development.

[7]  E. Miska,et al.  Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. , 2000, Genes & development.

[8]  A. Porter,et al.  Signal transduction pathways regulated by arsenate and arsenite , 1999, Oncogene.

[9]  R. Evans,et al.  Mechanism of corepressor binding and release from nuclear hormone receptors. , 1999, Genes & development.

[10]  C. Glass,et al.  Molecular determinants of nuclear receptor-corepressor interaction. , 1999, Genes & development.

[11]  A. Wolffe,et al.  Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. , 1999, Journal of molecular endocrinology.

[12]  M. Lazar,et al.  The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors , 1999, Nature.

[13]  P. Zhang,et al.  The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. , 1999, Journal of biological regulators and homeostatic agents.

[14]  T. Sternsdorf,et al.  PIC-1/SUMO-1-Modified PML-Retinoic Acid Receptor α Mediates Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia , 1999, Molecular and Cellular Biology.

[15]  S. Minucci,et al.  The APL-associated fusion proteins. , 1999, Haematologica.

[16]  D. Ayer,et al.  Histone deacetylases: transcriptional repression with SINers and NuRDs. , 1999, Trends in cell biology.

[17]  Paul Tempst,et al.  Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex , 1999, Nature.

[18]  C. Glass,et al.  Coactivator and corepressor complexes in nuclear receptor function. , 1999, Current opinion in genetics & development.

[19]  J. Qin,et al.  Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. , 1999, Molecules and Cells.

[20]  M. Privalsky,et al.  Transcriptional Silencing Is Defined by Isoform- and Heterodimer-Specific Interactions between Nuclear Hormone Receptors and Corepressors , 1998, Molecular and Cellular Biology.

[21]  N. Holbrook,et al.  Tumor Promoter Arsenite Activates Extracellular Signal-Regulated Kinase through a Signaling Pathway Mediated by Epidermal Growth Factor Receptor and Shc , 1998, Molecular and Cellular Biology.

[22]  P. Pandolfi,et al.  Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. , 1998, Blood.

[23]  C. Wong,et al.  Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor. , 1998, Molecular endocrinology.

[24]  M. Lanotte,et al.  Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. , 1998, Blood.

[25]  C. Glass,et al.  Co-activators and co-repressors in the integration of transcriptional responses. , 1998, Current opinion in cell biology.

[26]  A. Zelent,et al.  Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. , 1998, Blood.

[27]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  N. Weigel,et al.  The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor , 1998, Molecular and Cellular Biology.

[29]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[30]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[31]  C. Tribioli,et al.  Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL , 1998, Nature Genetics.

[32]  Jiahuai Han,et al.  The Stress Inducer Arsenite Activates Mitogen-activated Protein Kinases Extracellular Signal-regulated Kinases 1 and 2 via a MAPK Kinase 6/p38-dependent Pathway* , 1998, The Journal of Biological Chemistry.

[33]  C. Peschle,et al.  Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. , 1998, Journal of the National Cancer Institute.

[34]  Hui Li,et al.  Characterization of receptor interaction and transcriptional repression by the corepressor SMRT. , 1997, Molecular endocrinology.

[35]  M. Privalsky,et al.  A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release , 1997, Molecular and cellular biology.

[36]  A. Dejean,et al.  SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia , 1997 .

[37]  C. Glass,et al.  Differential effects of nuclear receptor corepressor (N-CoR) expression levels on retinoic acid receptor-mediated repression support the existence of dynamically regulated corepressor complexes. , 1997, Molecular endocrinology.

[38]  M. Pazin,et al.  What's Up and Down with Histone Deacetylation and Transcription? , 1997, Cell.

[39]  C. Niu,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.

[40]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[41]  H. de Thé,et al.  Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  T. Naoe,et al.  Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells. , 1997, International journal of hematology.

[43]  D. Moore,et al.  Two receptor interacting domains in the nuclear hormone receptor corepressor RIP13/N-CoR. , 1996, Molecular endocrinology.

[44]  Wilfred W. Li,et al.  The tumor promoter arsenite stimulates AP‐1 activity by inhibiting a JNK phosphatase. , 1996, The EMBO journal.

[45]  M. Downes,et al.  Two receptor interaction domains in the corepressor, N-CoR/RIP13, are required for an efficient interaction with Rev-erbA alpha and RVR: physical association is dependent on the E region of the orphan receptors. , 1996, Nucleic acids research.

[46]  C. Glass,et al.  A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains , 1996, Molecular and cellular biology.

[47]  K. Horwitz,et al.  Nuclear receptor coactivators and corepressors. , 1996, Molecular endocrinology.

[48]  M. Privalsky,et al.  Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. , 1996, Molecular endocrinology.

[49]  P. Chambon.  A decade of molecular biology of retinoic acid receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  Philip R. Cohen,et al.  Cellular stresses and cytokines activate multiple mitogen-activated-protein kinase kinase homologues in PC12 and KB cells. , 1996, European journal of biochemistry.

[51]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[52]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[53]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.

[54]  A. Dejean,et al.  The t(15;17) translocation in acute promyelocytic leukemia. , 1994, Pathologie-biologie.

[55]  J. Ham,et al.  Regulation of gene expression by nuclear hormone receptors. , 1989, Current opinion in cell biology.

[56]  P. Pandolfi,et al.  Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide , 2001 .

[57]  M. Luster,et al.  Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms? , 2000, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[58]  Yong-kui,et al.  Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. , 1999, Journal of the National Cancer Institute.

[59]  S. Waxman,et al.  Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. , 1999, Blood.

[60]  J. Slack.  Biology and treatment of acute progranulocytic leukemia. , 1999, Current opinion in hematology.

[61]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[62]  A. Dejean,et al.  Conjugation with the ubiquitin‐related modifier SUMO‐1 regulates the partitioning of PML within the nucleus , 1998, The EMBO journal.

[63]  J. Workman,et al.  Alteration of nucleosome structure as a mechanism of transcriptional regulation. , 1998, Annual review of biochemistry.

[64]  H. Li,et al.  Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. , 1998, Critical reviews in eukaryotic gene expression.

[65]  C. Meier.  Regulation of gene expression by nuclear hormone receptors. , 1997, Journal of receptor and signal transduction research.

[66]  G. Jenster,et al.  Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. , 1997, Recent progress in hormone research.

[67]  T. Naoe,et al.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. , 1996, Blood.

[68]  Qingbo Xu,et al.  Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. , 1996, Free radical biology & medicine.

[69]  P. Pandolfi.  PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia. , 1996, Haematologica.

[70]  H. de Thé.  Altered retinoic acid receptors. , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: From clinic to molecular biology , 1995, Stem cells.

[72]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.